Filtering

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 146 ()

1Dartmouth-Hitchcock Medical Center, Lebanon, United States 2Celgene Corporation, Summit, United States

DOP060

Real-world treatment pathway visualizations show low use of biologic therapies in Crohn's disease and ulcerative colitis in the United States

Year: 2017
Source:

1Dartmouth-Hitchcock Medical Center, Lebanon, United States 2Celgene Corporation, Summit, United States

Authors:

Siegel C.*1, Yang F.2, Eslava S.2, Cai J.2

DOP061

Intrauterine exposure to thiopurine: assessing health outcome of children born to patients with an inflammatory bowel disease

Year: 2016
Authors:

S. Kanis*, A. de Lima, C. van der Woude

Erasmus Medical Centre, Gastroenterology and Hepatology, Rotterdam, Netherlands

1Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea 2University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea 3Krasnoyarsk Regional clinical hospital, Krasnoyarsk, Russian Federation 4Nizhny Novgorod Regional Clinical Hospital n.a. N.A.Semashko, Nizhny Novgorod, Russian Federation 5Novosibirsk State Medical University, Novosibirsk, Russian Federation 6Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel and Sackler Faculty of Medicine, Tel Aviv University, Ramat-Gan, Israel 7Medical Center LLC Ukrainian German Antiulcer Gastroenterology Center BIK Kyiv, Kyiv, Ukraine 8Tolna Megyei Balassa János Kόrház, Szekszárd, Hungary 9Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 10Municipal Institution Odesa Regional Clinical Hospital, Odesa, Ukraine 11Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea 12Azienda Ospedaliera San Camillo Forlanini, Roma, Italy 13Gastroenterology Dept. at Colentina Clinical Hospital AND “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania 14St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, South Korea 15Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, South Korea 16CELLTRION, Inc., Incheon, South Korea

DOP061

Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results

Year: 2017
Source:

1Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea 2University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea 3Krasnoyarsk Regional clinical hospital, Krasnoyarsk, Russian Federation 4Nizhny Novgorod Regional Clinical Hospital n.a. N.A.Semashko, Nizhny Novgorod, Russian Federation 5Novosibirsk State Medical University, Novosibirsk, Russian Federation 6Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel and Sackler Faculty of Medicine, Tel Aviv University, Ramat-Gan, Israel 7Medical Center LLC Ukrainian German Antiulcer Gastroenterology Center BIK Kyiv, Kyiv, Ukraine 8Tolna Megyei Balassa János Kόrház, Szekszárd, Hungary 9Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 10Municipal Institution Odesa Regional Clinical Hospital, Odesa, Ukraine 11Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea 12Azienda Ospedaliera San Camillo Forlanini, Roma, Italy 13Gastroenterology Dept. at Colentina Clinical Hospital AND “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania 14St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, South Korea 15Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, South Korea 16CELLTRION, Inc., Incheon, South Korea

Authors:

Kim Y.H.*1, Ye B.D.2, Pesegova M.3, Alexeeva O.4, Osipenko M.5, Lahat A.6, Dorofeyev A.7, Salamon A.8, Fishman S.9, Levchenko O.10, Cheon J.H.11, Scribano M.L.12, Mateescu R.-B.13, Lee K.M.14, Eun C.S.15, Lee S.J.16, Lee S.Y.16

1Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway 2Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway 3Oslo University Hospital, Rikshospitalet, Department of Dermatology, Oslo, Norway 4Oslo University Hospital, Radiumhospitalet, Department of Medical Biochemistry, Oslo, Norway 5Ålesund Hospital, Department of Gastroenterology, Ålesund, Norway 6University of Oslo, Faculty of Medicine, Oslo, Norway 7Oslo University Hospital, Rikshospitalet, Department of Gastroenterology, Oslo, Norway 8Centre for Immune Regulation, Department of Immunology, Oslo, Norway 9Norwegian University of Science and Technology, Faculty of Medicine, Trondheim, Norway

DOP062

Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: explorative IBD subgroup-analyses in Crohn's disease and ulcerative colitis from the NOR-SWITCH trial

Year: 2017
Source:

1Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway 2Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway 3Oslo University Hospital, Rikshospitalet, Department of Dermatology, Oslo, Norway 4Oslo University Hospital, Radiumhospitalet, Department of Medical Biochemistry, Oslo, Norway 5Ålesund Hospital, Department of Gastroenterology, Ålesund, Norway 6University of Oslo, Faculty of Medicine, Oslo, Norway 7Oslo University Hospital, Rikshospitalet, Department of Gastroenterology, Oslo, Norway 8Centre for Immune Regulation, Department of Immunology, Oslo, Norway 9Norwegian University of Science and Technology, Faculty of Medicine, Trondheim, Norway

Authors:

Jørgensen K.K.*1, Olsen I.C.2, Goll G.L.2, Lorentzen M.3, Bolstad N.4, Berset I.P.5, Haavardsholm E.A.2,6, Lundin K.E.6,7,8, Mørk C.9, Kvien T.K.2,6, Jahnsen J.1,6 and the Nor-Switch Study Group

DOP062

Malignancy and mortality in paediatric-onset inflammatory bowel disease

Year: 2016
Authors:

L. de Ridder1, M. Joosse*2, D. Turner3, D. Wilson4, S. Koletzko5, J. Martin-de-Carpi6, U. Fagerberg7, C. Spray8, M. Sladek9, R. Shaoul10, E. Roma-Giannikou11, J. Bronsky12, D. Serban13, S. Cucchiara14, G. Veres15, F. Ruemmele16, I. Hojsak17, K. Kolho18, I. Davies19, M. Aloi20, P. Lionetti21, G. Veereman-Wauters22, C. Braegger23, E. Trindade24, A. V. Wewer25, A. Hauer26, A. Levine27

1Erasmus MC-Sophia Children’s Hospital, Department of Paediatric Gastroenterology, Rotterdam, Netherlands, 2Erasmus MC, Laboratory of Paediatrics, division Gastroenterology and Nutrition, Rotterdam, Netherlands, 3Shaare Zedek Medical Centre in Jerusalem, Department of Paediatric Gastroenterology, Jerusalem, Israel, 4University of Edinburgh, Department of Paediatric Gastroenterology, Child Life and Health, Edinburgh, United Kingdom, 5University of Munich Medical Centre, Dr. v. Hauner Children’s Hospital, Department of Paediatric Gastroenterology, Munich, Germany, 6Unidad para el Cuidado Integral de la Enfermedad Inflamatoria Intestinal Pediátrica, Sección de Gastroenterología, Hepatología y Nutrición Paediatrica, Hospital Sant Joan de Déu, Department of Paediatric Gastroenterology, Barcelona, Spain, 7Centre for Clinical Research, Västmanland Hospital, Västerås, Department of Paediatric Gastroenterology, Stockholm, Sweden, 8Bristol Royal Hospital for Children, Department of Paediatric Gastroenterology, Bristol, United Kingdom, 9Polish-American Children’s Hospital, Jagiellonian University Medical College, Department of Paediatrics, Gastroenterology and Nutrition, Cracow, Poland, 10Bnai Zion Medical Centre, Paediatric Day Care Unit, Department of Paediatrics, Haifa, Israel, 11Athens University, First Department of Paediatrics, Athens, Greece, 12Second Faculty of Medicine, Charles University and University Hospital Motol, Department of Paediatric Gastroenterology, Prague, Czech Republic, 13“Iuliu Hatieganu” University of Medicine and Pharmacy, Second Paediatric Clinic, Children’s Emergency Hospital, Department of Paediatric Gastroenterology, Cluj-Napoca, Romania, 14”La Sapienza” University, Department of Paediatric Gastroenterology, Rome, Italy, 15Semmelweis University, Department of Paediatric Gastroenterology, Budapest, Hungary, 16Université Paris Descartes, Sorbonne Paris Cité, Hôpital Necker-Enfants Malades, Department of Paediatric Gastroenterology, Paris, France, 17Referral Centre for Paediatric Gastroenterology, Children’s Hospital Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia, Croatia, 18Children’s Hospital, University Central Hospital and University of Helsinki, Department of Paediatric Gastroenterology, Helsinki, Finland, 19University Hospital of Wales, Department of Paediatric Gastroenterology, Cardiff, United Kingdom, 20Sapienza University of Rome, Department of Paediatric Gastroenterology, Rome, Italy, 21Meyer Children’s Hospital, Department of Paediatric Gastroenterology, Florence, Italy, 22University Hospital Brussels, UZBrussels, Department of Paediatric Gastroenterology and Nutrition, Brussels, Belgium, 23Children’s Research Centre, University Children’s Hospital, Department of Paediatric Gastroenterology and Nutrition, Zürich, Switzerland, 24Hospital São João, Paediatric Gastroenterology Unit, Porto, Portugal, 25University Hospital Hvidovre, Department of Paediatrics, Hvidovre, Denmark, 26Medical University of Graz, Paediatric Gastroenterology, Graz, Austria, 27The Wolfson Medical Centre, Tel-Aviv University, Department of Paediatric Gastroenterology, Tel-Aviv, Israel

DOP063

Measurement of endoscopic severity in a Crohns disease multicentre paediatric inception cohort: poor correlation of SES-CD with Paediatric Crohns Disease Activity Index (PCDAI)

Year: 2016
Authors:

N. Carman*1, P. Church1, H. Huynh2, D. Mack3, K. Jacobson4, A. Otley5, J. De Bruyn6, W. El-Matery7, C. Deslandres8, M. Carroll2, E. Wine2, E. Benchimol3, J. Van Limbergen5, A. Griffiths1, T. Walters1

1The Hospital for Sick Children, Toronto, Canada, 2University of Alberta, Edmonton, Canada, 3Children’s Hospital of Eastern Ontario, Ottawa, Canada, 4British Columbia Children’s Hospital, Vancouver, Canada, 5IWK Health Centre, Halifax, Canada, 6Alberta Children’s Hospital, Calgary, Canada, 7University of Manitoba, Winnipeg, Canada, 8Sainte-Justine University Hospital Centre, Montreal, Canada

DOP064

Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab

Year: 2016
Authors:

B. r*1, M. Yavzori1, O. Picard1, E. Fudim1, U. Kopylov1, E. Del Tedesco2, S. Paul2, Y. Chowers3, R. Eliakim1, S. Ben-Horin1, X. Roblin2

1Sheba Medical Centre & Sackler School of Medicine, Gastroenterology, Tel Hashomer, Israel, 2CHU de Saint-Etienne, Service de Gastrologie-Entérologie-Hépatologie, Saint-Etienne, France, 3Rambam Health Care Campus, Bruce & Ruth Rappaport School of Medicine, Technion Institute of Technology, Department of Gastroenterology, Haifa, Israel

DOP065

Less anti-infliximab antibody formation in paediatric Crohns patients on concomitant immunomodulators

Year: 2016
Authors:

H. Kansen1, P. van Rheenen2, R. Houwen1, W. Tjon A Ten3, G. Damen4, A. Kindermann5, J. Escher6, V. Wolters*1

1University Medical Centre-Wilhelmina Children’s Hospital, Department of Paediatric Gastroenterology, Utrecht, Netherlands, 2University of Groningen, University Medical Centre Groningen, Department of Paediatric Gastroenterology, Groningen, Netherlands, 3Maxima Medical Centre, Department of Paediatric Gastroenterology, Veldhoven, Netherlands, 4Radboud University Medical Centre-Amalia Children’s Hospital, Department of Paediatric Gastroenterology, Nijmegen, Netherlands, 5Emma Children´s Hospital, Academic Medical Centre, Department of Paediatric Gastroenterology, Amsterdam, Netherlands, 6, Erasmus Medical Centre-Sophia Children’s Hospital, Department of Paediatric Gastroenterology, Rotterdam, Netherlands

DOP066

Disappearance of anti-drug antibodies to infliximab and adalimumab after addition of an immunomodulator in patients with inflammatory bowel disease

Year: 2016
Authors:

A. Strik*1, G. van den Brink1, C. Ponsioen1, R. Mathot2, M. Löwenberg1, G. D’Haens1

1Academic Medical Centre, Gastroenterology and Hepatology, Amsterdam, Netherlands, 2Academic Medical Centre (AMC), Hospital Pharmacy, Amsterdam, Netherlands

DOP067

Factors influencing infliximab and adalimumab antibody formation and 6 month retrospective follow-up in a tertiary IBD centre

Year: 2016
Authors:

J. Digby-Bell*1, B. Warner1, E. Johnston1, N. Unsworth2, Z. Arkir2, J. Sanderson1, P. Irving1

1Guy’s and St Thomas’ NHS Foundation Trust, Gastroenterology, London, United Kingdom, 2Guy’s and St Thomas’ NHS Foundation Trust, Reference Chemistry, Biomedical Sciences, Viapath, London, United Kingdom

DOP068

Insufficient infliximab exposure predisposes to immunogenicity and enhanced clearance of infliximab in IBD

Year: 2016
Authors:

J. F. Brandse*1, D. R. Mould2, Y. K. Ashruf1, O. Smeekes1, S. Kuin1, A. Strik1, G.R. van den Brink1, G. R. D’Haens1

1Academic Medical Centre, Inflammatory Bowel Disease Centre, Amsterdam, Netherlands, 2Projections Research Inc, Projections Research Inc, Phoenixville, Pennsylvania, United States

DOP069

Dose optimisation using drug and antibody levels can benefit 50% patients prescribed anti-TNF therapy compared with empiric dose adjustment

Year: 2016
Authors:

P. Harrow*1, C. Skinner1, T. Hoque1, A. Ibarra1, J. Lindsay1, 2

1Barts Health NHS Trust, The Royal London Hospital, London, United Kingdom, 2Blizard Institute, Barts and The London School of Medicine and Dentistry, Centre for Immunobiology, London, United Kingdom

DOP070

The relationship between vedolizumab drug concentrations at or before week 6 and remission at week 14 in ulcerative colitis patients from GEMINI 1

Year: 2016
Authors:

X. Roblin*1, M.T. Osterman2, S. Glover3, U. Navaneethan4, M. A. Popa5, T. Wyant6, A. James7, K. Lasch5, M. Rosario6

1CHU de Saint-Etienne, Saint-Etienne, France, 2Hospital of the University of Pennsylvania and the Presbyterian Medical Centre of Philadelphia, Philadelphia, Pennsylvania, United States, 3Southeastern Centre for Inflammatory Bowel Diseases/Affiliate Faculty Biomedical Engineering, University of Florida, Gastroenterology, Hepatology, and Nutrition, Gainesville, Florida, United States, 4Centre for Interventional Endoscopy, Florida Hospital, Orlando, Florida, United States, 5Takeda Pharmaceuticals USA, Inc, Deerfield, Illinois, United States, 6Takeda Pharmaceuticals International Co, Cambridge, Massachusetts, United States, 7Takeda Development Centre Europe Ltd, London, United Kingdom

1Osaka City General Hospital, Gastroenterology, Osaka, Japan 2Iwate Medical University, Division of Gastroenterology, Department of Medicine, Morioka, Japan 3Sapporo Kosei General Hospital, Inflammatory Bowel Disease Centre, Sapporo, Japan 4Kyorin University School of Medicine, Department of Internal Medicine, Tokyo, Japan 5School of Medicine, Sapporo Medical University, Department of Gastroenterology and Hepatology, Sapporo, Japan 6Tokyo Yamate Medical Centre, Department of Medicine, Division of Gastroenterology, Tokyo, Japan 7Oita Red Cross Hospital, Department of Gastroenterology, Oita, Japan 8Saitama Medical Centre, Saitama Medical University, Department of Gastroenterology and Hepatology, Kawagoe, Japan 9Graduate School of Medicine, Chiba University, Department of Gastroenterology and Nephrology, Chiba, Japan 10Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan 11Graduate School of Medical Sciences, Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan 12Fukuoka University Chikushi Hospital, Department of Gastroenterology, Fukuoka, Japan 13Kyoto Prefectural University of Medicine, Department of Molecular Gastroenterology and Hepatology, Kyoto, Japan 14School of Medicine, Keio University, Department of Internal Medicine, Tokyo, Japan 15Toho University Sakura Medical Center, Department of Internal Medicin, Chiba, Japan 16Institute of Medical Science Hospital, University of Tokyo, Centre for Translational Research, Tokyo, Japan 17Kitasato University Kitasato Institute Hospital, Centre for Advanced IBD Research and Treatment, Tokyo, Japan

DOP071

Comparison of endoscopic responses to adalimumab monotherapy and combination therapy with azathioprine in patients with Crohn's disease: a sub-analysis of DIAMOND trial

Year: 2017
Source:

1Osaka City General Hospital, Gastroenterology, Osaka, Japan 2Iwate Medical University, Division of Gastroenterology, Department of Medicine, Morioka, Japan 3Sapporo Kosei General Hospital, Inflammatory Bowel Disease Centre, Sapporo, Japan 4Kyorin University School of Medicine, Department of Internal Medicine, Tokyo, Japan 5School of Medicine, Sapporo Medical University, Department of Gastroenterology and Hepatology, Sapporo, Japan 6Tokyo Yamate Medical Centre, Department of Medicine, Division of Gastroenterology, Tokyo, Japan 7Oita Red Cross Hospital, Department of Gastroenterology, Oita, Japan 8Saitama Medical Centre, Saitama Medical University, Department of Gastroenterology and Hepatology, Kawagoe, Japan 9Graduate School of Medicine, Chiba University, Department of Gastroenterology and Nephrology, Chiba, Japan 10Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan 11Graduate School of Medical Sciences, Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan 12Fukuoka University Chikushi Hospital, Department of Gastroenterology, Fukuoka, Japan 13Kyoto Prefectural University of Medicine, Department of Molecular Gastroenterology and Hepatology, Kyoto, Japan 14School of Medicine, Keio University, Department of Internal Medicine, Tokyo, Japan 15Toho University Sakura Medical Center, Department of Internal Medicin, Chiba, Japan 16Institute of Medical Science Hospital, University of Tokyo, Centre for Translational Research, Tokyo, Japan 17Kitasato University Kitasato Institute Hospital, Centre for Advanced IBD Research and Treatment, Tokyo, Japan

Authors:

Watanabe K.*1, Matsumoto T.2, Motoya S.3, Hisamatsu T.4, Nakase H.5, Yoshimura N.6, Ishida T.7, Kato S.8, Nakagawa T.9, Nagahori M.10, Esaki M.11, Matsui T.12, Naito Y.13, Kanai T.14, Suzuki Y.15, Nojima M.16, Watanabe M.10, Hibi T.17

DOP071

Tofacitinib plasma concentration monitoring is not needed for optimisation of induction therapy in moderate-to-severe ulcerative colitis: results of pooled exposure-response analyses of Phase 3 induction studies

Year: 2016
Authors:

A. Mukherjee1, S. Tsuchiwata2, C. Deng3, C. Vong4, R. Xie3, S.W. Martin4, D. Yu5, D. Woodworth5, W. Niezychowski5, C. Su*5

1Pfizer Inc, Groton, United States, 2Pfizer Japan Inc, Tokyo, Japan, 3Pfizer Inc, Shanghai, China, 4Pfizer Inc, Cambridge, United States, 5Pfizer Inc, Collegeville, Pennsylvania, United States

DOP072

Association of ustekinumab trough concentrations with clinical, biochemical, and endoscopic outcomes

Year: 2016
Authors:

R. Battat1, U. Kopylov*2, T. Bessissow1, A. Bitton1, A. Cohen3, M. Martel1, E. G. Seidman4, W. Afif4

1McGill University Health Centre, Gastroenterology, Montreal, Canada, 2Sheba Medical Centre, Gastroenterology, Tel Hashomer, Israel, 3Jewish General Hospital, Department of Gastroenterology, Montreal, Canada, 4McGill University, Division of Gastroenterology, Montreal Quebec, Canada

DOP073

Incidental diagnosis of inflammatory bowel disease through bowel cancer screening: a 7-year experience

U. Nosegbe*1, J. A. Scott1, R. O. Butcher1, 2, A. M. Abbasi1, R. C. Prudham1, R. George1, J. Limdi1, 2

Year: 2016
Authors:

1The Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom, 2University of Manchester, Institute of Inflammation and Repair, Manchester Academic Health Sciences Centre, Manchester, United Kingdom

Background: The UK Bowel Cancer Screening programme (BCSP) was launched in 2006 in England and following an age-extension, now screens individuals aged 60–74 years with a faecal occult blood test (FOBt) followed by screening colonoscopy if FOBt positive. We reported at ECCO 2012 the world’s first experience of incidental diagnosis of IBD through screening and now present an experience of incidental IBD over 7-years at our centre.

1Friedrich-Alexander University Erlangen-Nürnberg, Department of Medicine I, Erlangen, Germany 2Asklepios Westklinikum, Department of Internal Medicine/Gastroenterology, Hamburg, Germany 3Christian Albrechts University Kiel, Department of Internal Medicine/Gastroenterology, Kiel, Germany 4Klinikum Lüneburg, Klinik für Allgemeine Innere Medizin und Gastroenterologie, Lüneburg, Germany 5Uniklinik Köln, Klinik für Gastroenterologie und Hepatologie, Köln, Germany 6Universitätsklinikum Leipzig, Klinik und Poliklinik für Gastroenterologie und Rheumatologie, Leipzig, Germany 7Niigata University Medical and Dental Hospital, Niigata, Japan 8Stelic Institute & Co., Tokyo, Japan 9Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan

DOP073

Submucosal injection of the oligonucleotide STNM01 is able to induce clinical remission, mucosal healing and histological response in left-sided ulcerative colitis patients with moderate-to-severe disease

Year: 2017
Source:

1Friedrich-Alexander University Erlangen-Nürnberg, Department of Medicine I, Erlangen, Germany 2Asklepios Westklinikum, Department of Internal Medicine/Gastroenterology, Hamburg, Germany 3Christian Albrechts University Kiel, Department of Internal Medicine/Gastroenterology, Kiel, Germany 4Klinikum Lüneburg, Klinik für Allgemeine Innere Medizin und Gastroenterologie, Lüneburg, Germany 5Uniklinik Köln, Klinik für Gastroenterologie und Hepatologie, Köln, Germany 6Universitätsklinikum Leipzig, Klinik und Poliklinik für Gastroenterologie und Rheumatologie, Leipzig, Germany 7Niigata University Medical and Dental Hospital, Niigata, Japan 8Stelic Institute & Co., Tokyo, Japan 9Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan

Authors:

Atreya R.*1, Kühbacher T.2,3, Waldner M.J.1, Hirschmann S.1, Drvarov O.2, Abu Hashem R.2, Maaser C.4, Kucharzik T.4, Dinter J.5, Schramm C.5, Mertens J.5, Holler B.6, Mössner J.6, Suzuki K.7, Yokoyama J.7, Terai S.7, Yoneyama H.8, Asakura H.7, Hibi T.9, Neurath M.F.1

DOP074

Incidence and prediction of fistula formation in England

Year: 2016
Authors:

K. Sahnan*1, A. Askari1, S. Adegbola*1, P. Tozer1, R. Phillips1, A. Hart2, O. Faiz1

1St Mark’s Hospital, Colorectal Surgery, London, United Kingdom, 2St Mark’s Hospital, IBD/Physiology, London, United Kingdom

DOP075

Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel

Year: 2016
Authors:

C. Siegel1, C. Whitman2, B. Spiegel2, B. Feagan3, B. Sands4, E. Loftus5, R. Panaccione6, G. D’Haens7, C. Bernstein8, R. Gearry9, S. Ng10, G. Mantzaris11, B. Sartor12, M. Silverberg13, R. Riddell13, I. Koutroubakis14, C. O’Morain15, P. Lakatos16, D. McGovern2, J. Halfvarson17, W. Reinisch18, G. Rogler19, W. Kruis20, C. Tysk17, S. Schreiber21, S. Danese22, W. Sandborn23, A. Griffiths24, B. Moum25, C. Gasche26, F. Pallone27, S. Travis28, J. Panes29, J.-F. Colombel4, S. Hanauer30, L. Peyrin-Biroulet*31

1Geisel School of Medicine at Dartmouth, Inflammatory Bowel Disease Centre, Lebanon, New Hampshire, United States, 2Cedars-Sinai Medical Centre, Los Angeles, California, United States, 3Roberts Clinical Trials, London, Ontario, Canada, 4Icahn School of Medicine at Mount Sinai, New York, New York, United States, 5Mayo Clinic, Rochester, Minnesota, United States, 6University of Calgary, Calgary, Canada, 7Academic Medical Centre, Amsterdam, Netherlands, 8University of Manitoba, Winnipeg, Canada, 9University of Otago, Christchurch, New Zealand, 10Chinese University of Hong Kong, Hong Kong, Hong Kong, 11Evangelismos-PolyCliniki-Ophthalmiatreion Hospital, Athens, Greece, 12University of North Carolina, Chapel Hill, North Carolina, United States, 13Mount Sinai Hospital, Toronto, Canada, 14University Hospital Heraklion, Crete, Greece, 15Charlemont Clinic, Dublin, Ireland, 16Semmelweis University, Budapest, Hungary, 17Örebro University, Örebro, Sweden, 18McMaster University Medical Centre, Department of Gastroenterology, Hamilton, Canada, 19University Hospital Zürich, Clinic for Hepatology and Gastroenterology, Zürich, Switzerland, 20University of Cologne, Clinic for Internal Medicine, Koln, Germany, 21Universitätsklinikum Schleswig-Holstein Kiel, Clinic for Internal Medicine, Kiel, Germany, 22Humanitas University, Milan, Italy, 23University of California San Diego, San Diego, California, United States, 24Hospital for Sick Children, Toronto, Canada, 25Oslo University, Oslo, Norway, 26Medical University and General Hospital Vienna, Vienna, Austria, 27University Rome, Rome, Italy, 28Oxford University Hospital, Oxford, United Kingdom, 29Hospital Clinic de Barcelona, Barcelona, Spain, 30Northwestern Feinberg School of Medicine, Chicago, Illinois, United States, 31CHU Nancy, Department of Gastroenterology and Hepatology, Vandoeuvre-Lès-Nancy, France

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 146 ()